Home / INVESTING / Investing / Biotech stocks are at a critical juncture, strategist says

Biotech stocks are at a critical juncture, strategist says

Biotech stocks take lagged recently, as the Nasdaq biotech ETF, the IBB, has declined for three-straight sessions and is down multitudinous than 10 percent from its October high.

On a technical even, the group’s charts concern Miller Tabak equity strategist Matt Maley. Here’s why:

• On Wednesday, the ETF destitute below its 200-day moving average, which has proven regular support for the IBB for much of 2017. This is a red flag for the stocks into year-end and into 2018.

• The IBB has assembled nearly 16 percent this year but began pulling destroy in October. This raised concern that it could see a decline akin to the one in 2015 amongst political uncertainty around drug pricing.

• Two more key levels Maley is observant of are 105.5, which was the IBB’s high in early November and early December, and 101.5, which is the low lay a hand in August and November. A break below 101.5 would be quite bearish for the IBB.

Footing line: Biotech stocks just broke below their 200-day unstationary average, which could have negative implications for the group.

Check Also

Paul Tudor Jones says he likes bitcoin even more now, rally still in the ‘first inning’

Billionaire hedge assets manager Paul Tudor Jones has turned more bullish on bitcoin, calling it the …

Leave a Reply

Your email address will not be published. Required fields are marked *